Cancer Causes & Control

, Volume 27, Issue 2, pp 165–174

Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients

  • Thine Hvid
  • Birgitte Lindegaard
  • Kamilla Winding
  • Peter Iversen
  • Klaus Brasso
  • Thomas P. J. Solomon
  • Bente K. Pedersen
  • Pernille Hojman
Original paper

Abstract

Aim

Physical activity after prostate cancer diagnosis has been shown to reduce the risk of disease progression. Here, we aimed to evaluate the effect of a 2-year home-based endurance training intervention on body composition, biomarkers levels, and prostate-specific antigen (PSA) doubling time as a surrogate end-point for progressing disease.

Methods

Out-clinic patients with either biochemical recurrence following radical prostatectomy or patients managed on active surveillance were randomized to either 24 months (3 times/week) of home-based endurance training or usual care. Aerobic fitness, body composition, insulin sensitivity, and biomarkers were measured at 0, 6, and 24 months of intervention. PSA doubling time (PSADT) was calculated based on monthly PSA measurements.

Results

Twenty-five patients were enrolled, and 19 patients completed the study. PSADT increased in the training group from 28 to 76 months (p < 0.05) during the first 6 months and was correlated with changes in VO2max (p < 0.01, r2 = 0.41). The training group lost 3.6 ± 1.0 kg (p < 0.05) exclusively as fat mass, yet the changes in body composition were not associated with the increased PSADT. The training group showed significant improvements in plasma triglycerides, adiponectin, IGF-1, IGFBP-1, and fasting glucose levels, but no changes in insulin sensitivity (measured as Matsuda index), testosterone, cholesterols, fasting insulin, plasma TNF-alpha, IL-6, or leptin levels. The control group showed no changes in any of the evaluated parameters across the 2-year intervention.

Conclusion

In this small randomized controlled trial, we found that improvements in fitness levels correlated with increasing PSADT, suggesting a link between training and disease progression.

Keywords

PSA PSA doubling time Exercise Insulin sensitivity and body composition 

References

  1. 1.
    Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM (2011) Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 71(11):3889–3895PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29(6):726–732PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Payton S (2013) Prostate cancer: optimizing exercise interventions for men on ADT. Nat Rev Urol 10(11):615PubMedCrossRefGoogle Scholar
  4. 4.
    Culos-Reed SN, Robinson JW, Lau H et al (2010) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18(5):591–599PubMedCrossRefGoogle Scholar
  5. 5.
    Segal RJ, Reid RD, Courneya KS et al (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653–1659PubMedCrossRefGoogle Scholar
  6. 6.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347PubMedCrossRefGoogle Scholar
  7. 7.
    Hvid T, Winding K, Rinnov A et al (2013) Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr Relat Cancer 20(5):621–632PubMedCrossRefGoogle Scholar
  8. 8.
    Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470PubMedCrossRefGoogle Scholar
  9. 9.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRefGoogle Scholar
  10. 10.
    Ornish D, Weidner G, Fair WR et al (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174(3):1065–1069PubMedCrossRefGoogle Scholar
  11. 11.
    Frattaroli J, Weidner G, Dnistrian AM et al (2008) Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology 72(6):1319–1323PubMedCrossRefGoogle Scholar
  12. 12.
    Hebert JR, Hurley TG, Harmon BE, Heiney S, Hebert CJ, Steck SE (2012) A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. Cancer Epidemiol 36(2):e128–e136PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76(6):576–581PubMedCrossRefGoogle Scholar
  14. 14.
    Klotz L (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24(1):46–50PubMedCrossRefGoogle Scholar
  15. 15.
    Thomsen FB, Brasso K, Klotz L, Røder MA, Berg KD, Iversen P (2014) Active surveillance for clinically localized prostate cancer—a systematic review. J Surg Oncol 109(8):830–835PubMedCrossRefGoogle Scholar
  16. 16.
    Thomsen FB, Christensen IJ, Brasso K, Røder MA, Iversen P (2014) Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. BJU Int 113(5b):E98–E105PubMedCrossRefGoogle Scholar
  17. 17.
    McTiernan A (2008) Mechanisms linking physical activity with cancer. Nat Rev Cancer 8(3):205–211PubMedCrossRefGoogle Scholar
  18. 18.
    Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14(5):329–341PubMedCrossRefGoogle Scholar
  19. 19.
    Ornish D, Lin J, Chan JM et al (2013) Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol 14(11):1112–1120PubMedCrossRefGoogle Scholar
  20. 20.
    Park S, Kim TN, Nam J et al (2012) Recovery of overall exercise ability, quality of life, and continence after 12 week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomised controlled study. Urology 80:299–305PubMedCrossRefGoogle Scholar
  21. 21.
    Zopf EM, Bloch W, Machtens S, et al (2015) Effects of a 15-months supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProReHab study. Intergr Cancer Ther 14(5):409–418CrossRefGoogle Scholar
  22. 22.
    Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32(4):335–346PubMedCrossRefGoogle Scholar
  23. 23.
    Lakoski SG, Eves ND, Douglas PS, Jones LW (2012) Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 9(5):288–296PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Loprinzi PD, Kohli M (2013) Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003–2006. Mayo Clin Proc 88(1):11–21PubMedCrossRefGoogle Scholar
  25. 25.
    Burton AJ, Martin RM, Donovan JL et al (2012) Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. Cancer Epidemiol Biomark Prev 21(10):1877–1885CrossRefGoogle Scholar
  26. 26.
    Rundqvist H, Augsten M, Strømberg A et al (2013) Effect of acute exercise on prostate cancer cell growth. PLoS ONE 8(7):e67579PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P (2014) Muscle dysfunction in cancer patients. Ann Oncol 25(5):947–958PubMedCrossRefGoogle Scholar
  28. 28.
    Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4(4):486–501CrossRefGoogle Scholar
  29. 29.
    Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97PubMedCrossRefGoogle Scholar
  30. 30.
    Joshu CE, Mondul AM, Menke A et al (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res 4(4):544–551CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Thine Hvid
    • 1
  • Birgitte Lindegaard
    • 1
  • Kamilla Winding
    • 1
  • Peter Iversen
    • 2
  • Klaus Brasso
    • 2
  • Thomas P. J. Solomon
    • 1
    • 3
  • Bente K. Pedersen
    • 1
  • Pernille Hojman
    • 1
  1. 1.The Centre of Inflammation and Metabolism, Centre of Physical Activity Research, Department of Infectious Diseases, Rigshospitalet, Faculty of Health SciencesUniversity of CopenhagenCopenhagenDenmark
  2. 2.Department of Urology, Copenhagen Prostate Cancer CenterRigshospitaletCopenhagenDenmark
  3. 3.Department of Biomedical Sciences, Panum InstituteUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations